+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hyperplasia Therapeutics Market - Global Forecast 2026-2032- Product Image
Benign Prostatic Hyperplasia Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Benign Prostatic Hyperplasia Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6081737
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Benign Prostatic Hyperplasia Therapeutics Market is projected to reach USD 7.06 Billion in 2026. It is expected to continue growing at a CAGR of 9.91%, reaching USD 12.41 Billion by 2032.

Benign Prostatic Hyperplasia Therapeutics: Executive Overview

Benign prostatic hyperplasia (BPH) is a common, noncancerous enlargement of the prostate that can produce lower urinary tract symptoms, including weak urinary flow, urgency, frequency, nocturia, and incomplete emptying. Therapeutic management spans behavioral measures, prescription medicines, minimally invasive procedures, and surgery. Treatment selection is shaped by symptom burden, prostate anatomy, urinary complications, comorbidities, patient preferences, and the risk of disease progression. Clinical evaluation generally combines medical history, symptom assessment, physical examination, urinalysis, and selected testing such as prostate-specific antigen measurement, uroflowmetry, or post-void residual assessment when appropriate.

From Long-Term Medication to Anatomy-Directed Care

The treatment landscape is shifting toward more individualized care rather than a single default pathway. Alpha-blockers remain important for rapid symptom relief, while 5-alpha-reductase inhibitors are used when prostate enlargement and progression risk are clinically relevant. Combination therapy can be considered for appropriately selected patients, and phosphodiesterase-5 inhibitors may be useful when urinary symptoms coexist with erectile dysfunction. Increasing attention to minimally invasive options reflects demand for durable symptom improvement with less tissue disruption and shorter recovery than traditional surgery. Shared decision-making is becoming more important as clinicians balance efficacy, sexual side effects, retreatment considerations, anesthesia exposure, and access to specialist care.

Artificial Intelligence Strengthens Diagnosis, Triage, and Treatment Selection

Artificial intelligence is most relevant as a decision-support layer across the BPH care pathway. Machine-learning systems can help identify symptom patterns, interpret uroflowmetry or imaging data, prioritize patients for evaluation, and support risk stratification when integrated with validated clinical variables. Natural-language processing may assist with extracting urinary symptoms and treatment history from clinical records, while remote-monitoring tools can track symptom scores, medication persistence, and postoperative recovery. These applications require representative datasets, external validation, transparent performance measures, privacy safeguards, and clinician oversight. AI should augment-not replace-clinical judgment, particularly where symptoms may reflect infection, malignancy, neurogenic bladder, or other causes.

Regional Insights: Uneven Access Shapes BPH Treatment Pathways

North America generally benefits from broad availability of prescription therapies, diagnostic testing, and procedural expertise, although affordability and specialist access remain relevant. Europe combines established medical and surgical pathways with increasing interest in minimally invasive therapies, while national reimbursement and guideline implementation differ across countries. Asia-Pacific contains highly diverse health systems, with advanced procedural capacity in some settings and limited diagnostic or specialist access in others. Latin America faces variation in medicine availability, public-sector capacity, and referral pathways. In the Middle East, urban specialist centers may offer advanced interventions alongside access gaps outside major cities. Africa continues to face constraints involving urological workforce capacity, diagnostic infrastructure, medicine continuity, and timely referral, making adaptable and resource-conscious care models important.

Group Insights: Regional Blocs Reveal Different Access and Policy Priorities

ASEAN markets reflect wide differences in healthcare financing, specialist density, urbanization, and availability of minimally invasive procedures, creating a need for flexible treatment pathways. BRICS members combine large patient populations with varied public and private delivery systems; priorities commonly include earlier diagnosis, affordable medicines, and expanded urological capacity. The European Union benefits from shared scientific and regulatory cooperation, but reimbursement, procurement, and clinical implementation remain nationally determined. G7 health systems generally have strong diagnostic and procedural capabilities while confronting aging populations, care costs, and pressure to demonstrate value. GCC countries often possess well-resourced urban hospitals but must also address workforce specialization and access beyond major centers. NATO members span diverse health systems, so collaboration on clinical standards and continuity of care does not eliminate national differences in access or reimbursement.

Country Insights: National Health-System Differences Drive Adoption

Australia combines established primary care and specialist services with geographic access challenges. Brazil must navigate substantial public-private differences and uneven specialist distribution. Canada has strong clinical expertise but faces referral and procedure-access constraints across large distances. China is expanding healthcare capacity while addressing regional variation and an aging population. France, Germany, Italy, and Spain have mature European care systems, with differences in reimbursement, referral organization, and uptake of procedures. India faces major variation between metropolitan and rural services, alongside demand for affordable, scalable care. Japan and South Korea have advanced clinical infrastructure and aging populations, with attention to functional outcomes and efficient care delivery. Mexico experiences uneven access between urban and rural settings. Russia’s pathway is influenced by regional healthcare variation and access to specialized services. The United Kingdom emphasizes guideline-based assessment within a publicly funded system, while the United States combines broad therapeutic choice with pronounced differences in insurance coverage, affordability, and specialist access.

Action Priorities for Leaders in BPH Therapeutics

Industry leaders should prioritize evidence that compares symptom relief, functional outcomes, adverse effects, durability, and retreatment across clinically relevant patient groups. Product and service strategies should support shared decision-making with clear information on sexual health, recovery time, medication persistence, and when escalation is appropriate. Access plans should include affordable treatment options, primary-care education, referral support, and procedural training adapted to local capacity. Digital and AI tools should be developed with clinical partners, validated across diverse populations, and governed through strong privacy, cybersecurity, and human-oversight processes. Partnerships with health systems can improve diagnosis and follow-up, while real-world evidence can clarify how therapies perform outside controlled studies without substituting for rigorous clinical evaluation.

Research Methodology for a Clinically Grounded Executive Summary

This summary applies a structured review of established clinical concepts in BPH management, including symptom evaluation, pharmacologic classes, minimally invasive interventions, surgery, patient selection, and health-system access. Regional, group, and country observations are framed as qualitative differences in healthcare infrastructure, demographics, reimbursement, specialist availability, and implementation conditions rather than quantified commercial outcomes. Interpretation should be triangulated against current urological guidelines, peer-reviewed clinical literature, regulatory information, health-system publications, and validated outcomes research. AI-related statements are limited to documented or clinically plausible decision-support uses and emphasize validation, bias assessment, privacy, and clinician accountability.

Conclusion: Better Outcomes Depend on Personalization and Access

BPH therapeutics are evolving from symptom control alone toward individualized, anatomy-aware, and preference-sensitive care. Medicines remain central, while minimally invasive and surgical options provide important pathways for persistent symptoms, complications, or medication intolerance. Artificial intelligence may improve triage, monitoring, and treatment selection, but only when embedded within safe clinical governance. Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific-and within the specified country and economic groups-outcomes will depend on matching evidence-based interventions to local resources, patient needs, and equitable access.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Benign Prostatic Hyperplasia Therapeutics Market, by Dosage Form
7.1. Introduction
7.2. Capsule
7.3. Liquid
7.4. Tablet
8. Benign Prostatic Hyperplasia Therapeutics Market, by Therapy Type
8.1. Introduction
8.2. 5-Alpha Reductase Inhibitors
8.2.1. Dutasteride
8.2.2. Finasteride
8.3. Alpha Blockers
8.3.1. Alfuzosin
8.3.2. Doxazosin
8.3.3. Tamsulosin
8.3.4. Terazosin
8.4. Combination Therapies
8.5. Phytotherapeutics
8.5.1. Beta-Sitosterol
8.5.2. Pygeum
8.5.3. Saw Palmetto
9. Benign Prostatic Hyperplasia Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Online Pharmacies
9.3. Offline Pharmacies
10. Benign Prostatic Hyperplasia Therapeutics Market, by End User
10.1. Introduction
10.2. Homecare
10.3. Hospitals
10.4. Urology Clinics
11. Benign Prostatic Hyperplasia Therapeutics Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Benign Prostatic Hyperplasia Therapeutics Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Benign Prostatic Hyperplasia Therapeutics Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. AbbVie Inc.
15.3. Astellas Pharma Inc.
15.4. Bayer AG
15.5. Boehringer Ingelheim Pharma GmbH & Co. KG
15.6. Boston Scientific Corporation
15.7. Cipla Ltd.
15.8. Coloplast Group
15.9. Cook Group
15.10. Eli Lilly and Company
15.11. Endo Pharmaceuticals Inc.
15.12. GlaxoSmithKline plc
15.13. Johnson & Johnson
15.14. KARL STORZ SE & Co. KG
15.15. Merck & Co., Inc.
15.16. Olympus Corporation
15.17. Pfizer Inc.
15.18. Sanofi S.A.
15.19. Sun Pharmaceutical Industries Ltd.
15.20. Teleflex Incorporated
15.21. Teva Pharmaceutical Industries Ltd.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Benign Prostatic Hyperplasia Therapeutics Market, Years Considered for the Study
FIGURE 2. Global Benign Prostatic Hyperplasia Therapeutics Market, Research Design
FIGURE 3. Global Benign Prostatic Hyperplasia Therapeutics Market, Research Framework
FIGURE 4. Global Benign Prostatic Hyperplasia Therapeutics Market, Data Triangulation
FIGURE 5. Global Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 7. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 9. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Benign Prostatic Hyperplasia Therapeutics Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Benign Prostatic Hyperplasia Therapeutics Market Segmentation & Coverage
TABLE 2. Global Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 4. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Liquid Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Liquid Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Liquid Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 14. Global 5-Alpha Reductase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global 5-Alpha Reductase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global 5-Alpha Reductase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Dutasteride Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Dutasteride Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Dutasteride Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Finasteride Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Finasteride Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Finasteride Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Alpha Blockers Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Alpha Blockers Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Alpha Blockers Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Alfuzosin Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Alfuzosin Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Alfuzosin Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Doxazosin Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Doxazosin Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Doxazosin Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Tamsulosin Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Tamsulosin Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Tamsulosin Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Terazosin Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Terazosin Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Terazosin Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Combination Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Combination Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Combination Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Phytotherapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Phytotherapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Phytotherapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Beta-Sitosterol Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Beta-Sitosterol Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Beta-Sitosterol Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Pygeum Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Pygeum Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Pygeum Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Saw Palmetto Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Saw Palmetto Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Saw Palmetto Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 54. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Offline Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Offline Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Offline Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 61. Global Homecare Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Homecare Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Homecare Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Urology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Urology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Urology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. North America Benign Prostatic Hyperplasia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. North America Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 81. North America Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 82. North America Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 83. North America Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 84. North America Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 85. North America Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. North America Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 89. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 90. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 91. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 92. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 93. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 94. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 95. Europe Benign Prostatic Hyperplasia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Europe Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 97. Europe Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 98. Europe Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 99. Europe Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 100. Europe Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 101. Europe Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. Europe Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. Middle East Benign Prostatic Hyperplasia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Middle East Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 105. Middle East Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 106. Middle East Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 107. Middle East Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 108. Middle East Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 109. Middle East Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 110. Middle East Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. Africa Benign Prostatic Hyperplasia Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Africa Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 113. Africa Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 114. Africa Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 115. Africa Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 116. Africa Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 117. Africa Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 118. Africa Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. ASEAN Benign Prostatic Hyperplasia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. ASEAN Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 122. ASEAN Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 123. ASEAN Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 124. ASEAN Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 125. ASEAN Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 126. ASEAN Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. ASEAN Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. GCC Benign Prostatic Hyperplasia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. GCC Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 130. GCC Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 131. GCC Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 132. GCC Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 133. GCC Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 134. GCC Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 135. GCC Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. European Union Benign Prostatic Hyperplasia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. European Union Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 138. European Union Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 139. European Union Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 140. European Union Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 141. European Union Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 142. European Union Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 143. European Union Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. BRICS Benign Prostatic Hyperplasia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. BRICS Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 146. BRICS Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 147. BRICS Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 148. BRICS Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 149. BRICS Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 150. BRICS Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 151. BRICS Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 152. G7 Benign Prostatic Hyperplasia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 153. G7 Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 154. G7 Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 155. G7 Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 156. G7 Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 157. G7 Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 158. G7 Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. G7 Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. NATO Benign Prostatic Hyperplasia Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 161. NATO Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 162. NATO Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 163. NATO Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 164. NATO Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 165. NATO Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 166. NATO Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. NATO Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. Global Benign Prostatic Hyperplasia Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 169. United States Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 170. United States Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 171. United States Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 172. United States Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 173. United States Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 174. United States Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 175. United States Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 176. United States Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Canada Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 178. Canada Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 179. Canada Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 180. Canada Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 181. Canada Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 182. Canada Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 183. Canada Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. Canada Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 186. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 187. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 188. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 189. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 190. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 191. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 192. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 194. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 195. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 196. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 197. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 198. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 199. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 200. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. United Kingdom Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 202. United Kingdom Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 203. United Kingdom Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 204. United Kingdom Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 205. United Kingdom Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 206. United Kingdom Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 207. United Kingdom Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 208. United Kingdom Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. Germany Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 210. Germany Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 211. Germany Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 212. Germany Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 213. Germany Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 214. Germany Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 215. Germany Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. Germany Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. France Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 218. France Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 219. France Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 220. France Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 221. France Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 222. France Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 223. France Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 224. France Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 225. Russia Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 226. Russia Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 227. Russia Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 228. Russia Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 229. Russia Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 230. Russia Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 231. Russia Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. Russia Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. Italy Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 234. Italy Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 235. Italy Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 236. Italy Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 237. Italy Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 238. Italy Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 239. Italy Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 240. Italy Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. Spain Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 242. Spain Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 243. Spain Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 244. Spain Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 245. Spain Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 246. Spain Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 247. Spain Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 248. Spain Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 249. China Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 250. China Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 251. China Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 252. China Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 253. China Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 254. China Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 255. China Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 256. China Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. India Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 258. India Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 259. India Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 260. India Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 261. India Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 262. India Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 263. India Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 264. India Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 265. Japan Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 266. Japan Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 267. Japan Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 268. Japan Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 269. Japan Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 270. Japan Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 271. Japan Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 272. Japan Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 273. Australia Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 274. Australia Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 275. Australia Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 276. Australia Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 277. Australia Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 278. Australia Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 279. Australia Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 280. Australia Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 282. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 283. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 284. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 285. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 286. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size, by Phytotherapeutics, 2017-2032 (USD Million)
TABLE 287. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 288. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 289. Global Benign Prostatic Hyperplasia Therapeutics Market Share, by Key Player, 2025
TABLE 290. Global Benign Prostatic Hyperplasia Therapeutics Market, Key Experts

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Coloplast Group
  • Cook Group
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Merck & Co., Inc.
  • Olympus Corporation
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.

Related Topics

Related Reports

Benign Prostatic Hyperplasia Treatment Market - Global Forecast 2026-2032 - Product Image

Benign Prostatic Hyperplasia Treatment Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report - Product Image

Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report

  • Report
  • 210 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Report 2026 - Product Image

Benign Prostatic Hyperplasia Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends and Forecast by Treatment Type, and Region, 2026-2034 - Product Image

Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends and Forecast by Treatment Type, and Region, 2026-2034

  • Report
  • 145 Pages
  • Global
From
Drugs for Benign Prostatic hypertrophy Market Report 2026 - Product Image

Drugs for Benign Prostatic hypertrophy Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.